ACNM First Annual International Session: Frontiers of Nuclear Medicine and PET

Thursday, January 28
1:15 PM–3:15 PM

Location: North Ballroom (Hilton Orlando Lake Buena Vista on Hotel Plaza Blvd)

Education: CE Session

Sponsored by: American College of Nuclear Medicine

CME: 2.00
ACPE: 2.00 [0210-0000-16-009-L04-P]
VOICE A+: 2.00
CAMPEP: 2.00

Educational Objectives
Upon completion of this activity, the participant will be able to:
1. Discuss the frontiers of clinical practice of nuclear medicine and PET/CT in China
2. Describe the value of Y90-microsphere treatment for primary and metastatic liver tumors
3. Discuss THERANOSTICS of Prostate Cancer Using Ga-68 and Lu-177 Labeled PSMA Small Molecules


1:15 PM - 1:55 PM
The Challenge and Opportunity of Nuclear Medicine and PET in China
Yaming Li, MD

1:55 PM - 2:35 PM
Y90 Microsphere Treatment for Primary & Metastatic Liver Tumors
Fani Murat Bozkurt, MD

2:35 PM - 3:15 PM
Advancing Personalized Nuclear Medicine by THERANOSTICS of Prostate Cancer Using Ga68 and Lu177 Labeled PSMA Molecules
Richard P. Baum, MD, PhD

Session Leaders

Organizer: Rathan M. Subramaniam, MD, PhD, MPH, FACNM;
Moderator: Saabry Osmany, MD, FACNM; David Ng, MD;